Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials).
C
C
Kelaidi
L
L
Ades
S
S
Chevret
M
M
Sanz
A
A
Guerci
X
X
Thomas
S
S
de Botton
E
E
Raffoux
C
C
Rayon
N
N
Fegueux
D
D
Bordessoule
F
F
Rigal-Huguet
H
H
Link
A
A
Stoppa
A
A
Vekhoff
S
S
Meyer-Monard
S
S
Castaigne
H
H
Dombret
L
L
Degos
P
P
Fenaux
D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005060:Europe; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010087:Oxides / Q000627:therapeutic use; D011379:Prognosis; D012008:Recurrence; D012307:Risk Factors; D016896:Treatment Outcome; D014212:Tretinoin / Q000008:administration & dosage*
D018943:Anthracyclines; D001152:Arsenicals; D010087:Oxides; D014212:Tretinoin; D000077237:Arsenic Trioxide